The DOI matches its Crossref record.
Dose Increase Versus Unchanged Continuation of Antidepressants After Initial Antidepressant Treatment Failure in Patients With Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized, Double-Blind Trials
Abstract
OBJECTIVE: To evaluate the efficacy and tolerability of dose increase compared to dose continuation of the initially prescribed antidepressant in antidepressant treatment failure (ATF). DATA SOURCES: We searched CENTRAL, PubMed, Embase, and PsycINFO using generic terms for depression, dose increase, and randomized controlled trials (RCTs), without date or language restrictions. STUDY SELECTION: Of 1,780 studies screened, 9 studies reporting on 1,273 patients were included for meta-analysis (PROSPERO Registration: CRD42017058389). Studies met the following predetermined inclusion criteria: randomized controlled trial, patients diagnosed with unipolar depression according to a standardized diagnostic instrument, ATF after a standard antidepressant trial (duration of ≥ 3 weeks at a standard dose), dose increase regimen, and control group of dose continuation. DATA EXTRACTION: Two authors extracted data independently according to the Cochrane Handbook for Systematic Reviews. Analyses are based on random effects models. RESULTS: All studies reported on selective serotonin reuptake inhibitors (SSRIs); 1 study also reported on maprotiline. Meta-analyses resulted in a statistically nonsignificant summary effect size of 0.053 standardized mean difference (95% CI, -0.143 to 0.248) in favor of antidepressant dose increase. Subgroup and sensitivity analyses and secondary outcome analyses resulted in similar effect estimates and supported the robustness of the results. CONCLUSIONS: With clinically and statistically nonsignificant effect estimates, there is evidence from RCTs against increasing the dose of SSRIs (with the possible exception of citalopram) in adult patients with major depression and ATF. Dose increase with other antidepressants (eg, tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, monoamine oxidase inhibitors) and in other patient groups (minor depression, children and adolescents) or after long periods of first-line antidepressant therapy (ie, 8 weeks) have not been or not been sufficiently studied and, at this time, cannot be recommended in clinical practice.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“such strategies may, however, also largely be ineffective [4–7].”
From The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review (2022) · cites this paper as [6]
In the citing paper
“Common treatment strategies in patients with depression for whom antidepressant treatment has not been effective include increasing the antidepressant dose or switching to a different antidepressant”
From The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review (2022) · cites this paper as [6]
In the citing paper
“there is a limited benefit associated with increasing doses of SSRIs above the lower range of the licensed dose in general, whether using a fixed dosing regimen [4, 5], a flexible dosing regimen [46], or as a second-step strategy in patients not responding to standard dosing [6, 45].”
From The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review (2022) · cites this paper as [6]
Citations
Cited by
Thapar, A., Eyre, O., Patel, V., & Brent, D. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01012-1 · Cited by 869
Henssler, J., Alexander, D., Schwarzer, G., Bschor, T., & Baethge, C. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.4313 · Cited by 111
Self-citationSørensen, A., Ruhé, H. G., & Munkholm, K. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01285-w · Cited by 65
Braun, C., Adams, A., Rink, L., Bschor, T., Kuhr, K., & Baethge, C. (2020) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13235 · Cited by 36
Self-citationRink, L., Adams, A., Braun, C., Bschor, T., Kuhr, K., & Baethge, C. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000520554 · Cited by 35
Self-citation
Metadata
- Authors
- Rink, L., Braun, C., Bschor, T., Henssler, J., Franklin, J., & Baethge, C.
- Affiliations
- University of Cologne (DE)
- Schlosspark-Klinik (DE)
- St. Hedwig-Krankenhaus (DE)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2018-06-27
- Volume
- 79
- Issue
- 3
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2803967896
- Cited by
- 31
- References
- 0
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2023: 4 · 2022: 5 · 2021: 7 · 2020: 3 · 2019: 5 · 2018: 2
- FWCI
- 2.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- antidepressant treatment failure, major depressive disorder, selective serotonin reuptake inhibitors, citalopram, maprotiline, antidepressant efficacy, antidepressant tolerability
- MeSH terms
- Major Depressive Disorder, Humans, Randomized Controlled Trials as Topic, Outcome Assessment, Health Care, Treatment Failure, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dose Increase Versus Unchanged Continuation of Antidepressants After Initial Antidepressant Treatment Failure in Patients With Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized, Double-Blind Trials. https://app.cochat.ai/papers/10.4088/jcp.17r11693
- The paper
- Rink, L., Braun, C., Bschor, T., Henssler, J., Franklin, J., & Baethge, C. (2018). Dose Increase Versus Unchanged Continuation of Antidepressants After Initial Antidepressant Treatment Failure in Patients With Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized, Double-Blind Trials. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.17r11693
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.